Marco Mottinelli,
Assistant Scientist
Department:
Medicinal Chemistry
Business Phone:
(352) 273-7714
Business Email:
m.mottinelli@cop.ufl.edu
About Marco Mottinelli
Marco Mottinelli received his master’s degree in Chemistry and Pharmaceutical Technology at the University of Pisa, Italy. After graduating, he spent one year at DSM pharmaceutical products, the Netherlands, before moving to the University of Bath, England to pursue his Doctorate degree in medicinal chemistry. Upon completion of his Ph.D. on the synthesis and biological evaluation of novel chemical entities targeting estrogen biosynthesis and signaling for the treatment of breast cancer, Mottinelli moved to the University of Mississippi as a postdoctoral associate within the group of Dr. Christopher McCurdy. In 2017, Dr. Mottinelli joined the University of Florida as a postdoctoral research associate in the department of Medicinal Chemistry and in 2020 he obtained the Research Assistant position. His research focuses on the development of neurotherapeutics in the areas of pain and drug of abuse and more specifically on Neuropeptide FF receptor and Sigma receptors ligands.
Teaching Profile
Courses Taught
2020-2021
PHA6447 Drug Design
Publications
2022
Differential Peripheral Blood Glycoprotein Profiles in Symptomatic and Asymptomatic COVID-19
Viruses.
14(3)
[DOI] 10.3390/v14030553.
[PMID] 35336960.
2022
The Lack of Contribution of 7-Hydroxymitragynine to the Antinociceptive Effects of Mitragynine in Mice: A Pharmacokinetic and Pharmacodynamic Study.
Drug metabolism and disposition: the biological fate of chemicals.
50(2):158-167
[DOI] 10.1124/dmd.121.000640.
[PMID] 34759012.
2021
A hypolipoprotein sepsis phenotype indicates reduced lipoprotein antioxidant capacity, increased endothelial dysfunction and organ failure, and worse clinical outcomes
Critical Care.
25(1)
[DOI] 10.1186/s13054-021-03757-5.
[PMID] 34535154.
2021
Activity of Mitragyna speciosa (“Kratom”) Alkaloids at Serotonin Receptors.
Journal of medicinal chemistry.
64(18):13510-13523
[DOI] 10.1021/acs.jmedchem.1c00726.
[PMID] 34467758.
2021
Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells.
Pathogens (Basel, Switzerland).
10(11)
[DOI] 10.3390/pathogens10111514.
[PMID] 34832669.
2021
Identification and characterization of MAM03055A: A novel bivalent sigma-2 receptor/TMEM97 ligand with cytotoxic activity.
European journal of pharmacology.
906
[DOI] 10.1016/j.ejphar.2021.174263.
[PMID] 34144027.
2021
Lipid and Lipoprotein Dysregulation in Sepsis: Clinical and Mechanistic Insights into Chronic Critical Illness
Journal of Clinical Medicine.
10(8)
[DOI] 10.3390/jcm10081693.
[PMID] 33920038.
2021
Lipid and lipoprotein predictors of functional outcomes and long-term mortality after surgical sepsis
Annals of Intensive Care.
11(1)
[DOI] 10.1186/s13613-021-00865-x.
[PMID] 34018068.
2021
N-Phenyl-1,2,3,4-tetrahydroisoquinoline: An Alternative Scaffold for the Design of 17β-Hydroxysteroid Dehydrogenase 1 Inhibitors.
ChemMedChem.
16(1):259-291
[DOI] 10.1002/cmdc.202000762.
[PMID] 33151004.
2021
Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for μ-Opioid Receptor and Opioid-Like Behavioral Effects in Rats.
The Journal of pharmacology and experimental therapeutics.
376(3):410-427
[DOI] 10.1124/jpet.120.000189.
[PMID] 33384303.
2021
Quantitative and Qualitative Assessments of Cholesterol Association With Bacterial Infection Type in Sepsis and Septic Shock
Journal of Intensive Care Medicine.
36(7):808-817
[DOI] 10.1177/0885066620931473.
[PMID] 32578468.
2020
Evaluation of 18F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration in vivo in rodents and in human tissue.
Theranostics.
10(18):7938-7955
[DOI] 10.7150/thno.47585.
[PMID] 32724451.
2020
Sequential Organ Failure Assessment Component Score Prediction of In-hospital Mortality From Sepsis
Journal of Intensive Care Medicine.
35(8):810-817
[DOI] 10.1177/0885066618795400.
[PMID] 30165769.
2019
Bioanalytical method development and validation of MES207, a neuropeptide FF receptor antagonist, and its application in preclinical pharmacokinetics.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
1134-1135
[DOI] 10.1016/j.jchromb.2019.121875.
[PMID] 31790916.
2019
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain.
Frontiers in pharmacology.
10
[DOI] 10.3389/fphar.2019.00678.
[PMID] 31258480.
2019
Divergent Cytotoxic and Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-Activity Relationships of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) Derivatives.
The Journal of pharmacology and experimental therapeutics.
368(2):272-281
[DOI] 10.1124/jpet.118.253484.
[PMID] 30530624.
2019
LIPid Intensive Drug therapy for Sepsis Pilot (LIPIDS-P): Phase I/II clinical trial protocol of lipid emulsion therapy for stabilising cholesterol levels in sepsis and septic shock
BMJ Open.
9(9)
[DOI] 10.1136/bmjopen-2019-029348.
[PMID] 31537565.
2018
HDL inflammatory index correlates with and predicts severity of organ failure in patients with sepsis and septic shock
PLOS ONE.
13(9)
[DOI] 10.1371/journal.pone.0203813.
[PMID] 30216360.
2017
Accessing simply-substituted 4-hydroxytetrahydroisoquinolines via Pomeranz-Fritsch-Bobbitt reaction with non-activated and moderately-activated systems.
Beilstein journal of organic chemistry.
13:1871-1878
[DOI] 10.3762/bjoc.13.182.
[PMID] 29062406.
2011
Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5.
Bioorganic & medicinal chemistry letters.
21(24):7331-6
[DOI] 10.1016/j.bmcl.2011.10.031.
[PMID] 22056743.
Contact Details
Phones:
- Business:
- (352) 273-7714
Emails:
- Business:
- m.mottinelli@cop.ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100485
Gainesville FL 32610 - Business Street:
-
COLLEGE OF PHARMACY – MEDICAL SCIENCES BUILD
P5-10/P6-07
1345 CENTER DR
GAINESVILLE FL 32611